Scarica l'app Stockscreener
41.67
3.69%
1.57
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Form 4 Edgewise Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant - Stock Titan
[144] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan
Edgewise lures 2 new employees with 16,500 stock options - Stock Titan
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now? - Insider Monkey
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Stocktwits
EWTX News | EDGEWISE THERAPEUTICS INC (NASDAQ:EWTX) - ChartMill
Edgewise Therapeutics, Inc. Actuals & Estimates (NASDAQ:EWTX) - TradingView
(EWTX) Risk Channels and Responsive Allocation - Stock Traders Daily
EWTX Forecast — Price Target — Prediction for 2027 - TradingView
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data - Yahoo Finance
Edgewise Therapeutics stock surges 8.94% to $42.30 as company gears up for EAN poster reveal - Traders Union
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release - Sahm
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
Edgewise Therapeutics stock hits all-time high at 40.87 USD - Investing.com
Edgewise Therapeutics stock hits all-time high at 40.87 USD By Investing.com - Investing.com Australia
Edgewise Therapeutics stock jumps 5.89 percent as company readies for BIO 2026 event - Traders Union
RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk - Moomoo
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - Moomoo
Edgewise Therapeutics Inc (EWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Edgewise Therapeutics Inc (EWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Edgewise Therapeutics Inc (EWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Edgewise Therapeutics Inc (EWTX) Institutional Confidence - TradingKey
Edgewise Therapeutics Inc (EWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $41 to $59 - Moomoo
Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59 - Stock Titan
Edgewise Therapeutics (EWTX) director receives grant of 16,377 stock options - Stock Titan
Director at Edgewise (NASDAQ: EWTX) awarded 16,377 stock options - Stock Titan
Edgewise Therapeutics Inc (EWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EWTX Maintained by Goldman Sachs -- Price Target Raised to $32.0 - GuruFocus
RBC Capital raises Edgewise Therapeutics price target on trial data By Investing.com - Investing.com Canada
Edgewise Therapeutics Inc (EWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edgewise shares slip despite positive Phase II HCM data for EDG-7500 - The Pharma Letter
Edgewise Therapeutics Inc (EWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic CardiomyopathySlideshow (NASDAQ:EWTX) 2026-06-17 - Seeking Alpha
Edgewise shares slip after heart-disease drug trial data disappoints investors - 1470 & 100.3 WMBD
Edgewise Therapeutics (NASDAQ: EWTX) grants director equity awards - Stock Titan
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan
Edgewise Edges Into Phase III With EDG-7500 - Citeline News & Insights
EWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
EWTX: EDG-7500 showed strong efficacy and safety in HCM, enabling echo-independent dosing - TradingView
Edgewise Therapeutics (EWTX) Shares Plunge 25% After Trial Update - GuruFocus
Edgewise Therapeutics Reports Improvements In Heart Drug Trial - Benzinga
Edgewise heart drug passes key trial test - BioPharma Dive
Edgewise Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co. - Moomoo
Edgewise heads to phase III with solid EDG-7500 data in HCM - BioWorld News
Edgewise Therapeutics (EWTX) Sees Significant Drop in Share Price - GuruFocus
Edgewise Therapeutics reports positive Phase 2 heart data - grafa.com
Edgewise reports phase 2 trial results for heart disease drug By Investing.com - Investing.com South Africa
Edgewise Therapeutics stock tumbles 25% on trial data By Investing.com - Investing.com South Africa
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - BioSpace
Edgewise posts trial data for heart disease drug (EWTX:NASDAQ) - Seeking Alpha
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall By Investing.com - Investing.com Nigeria
SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall - Investing.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
1.05%
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):